Navigation Links
SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes

AMSTERDAM, August 17 /PRNewswire/ -- SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel GLP-1 analog for monthly dosing to treat type 2 diabetes Under the agreement, SynCo will further develop the Versartis existing production process for VRS-859 and optimize the manufacturing process to increase yields for the forthcoming cGMP production.

VRS-859 is a recombinant fusion protein containing exenatide and XTEN(TM), a novel hydrophilic amino acid sequence that prolongs the half life of proteins and peptides. New therapeutic compounds using the XTEN technology are expected to provide enhanced stability and less frequent dosing requirements with potentially fewer patient side effects.

"Versartis selected SynCo because of its extensive pharmaceutical manufacturing experience and its ability to deliver bulk and final product for clinical trials and ultimately, for commercialization," said Jeffrey L. Cleland, Ph.D., Founder and Chief Executive Officer of Versartis. "We expect SynCo to ensure our goal of initiating Phase 1 clinical trials for VRS-859 in the first half of 2010. SynCo will also become our preferred manufacturing partner for future Versartis products based on the XTEN technology, which have similar production processes."

Pierre Warffemius, SynCo Bio Partners Chief Executive Officer commented, "We are delighted that SynCo has been chosen to develop and manufacture Versartis' lead compound VRS-859. As Versartis looks to advance its novel product portfolio through clinical trials, we look forward to a long and successful collaboration with this exciting new company."

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience with mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producing a wide variety of different vaccines, live bacterial products and recombinant proteins in our state-of-the-art, GMP-licensed facilities since inception in 2000.

Focused solely on biopharmaceuticals, SynCo Bio Partners acts as a strategic, long-term partner delivering product on time to the highest quality standards. SynCo's team is committed to exceeding customer expectations by taking a truly collaborative approach to manufacturing. For more information, please visit

About Versartis

Versartis, Inc., a Redwood City, California biotechnology company, is developing therapeutics for the treatment of metabolic diseases and endocrine disorders. Versartis is pursuing the development of new therapeutic proteins utilizing the Amunix Inc. novel half-life extension XTEN(TM) technology.

Versartis, a joint venture company between Amunix, Inc. and Index Ventures, owns and develops the novel drug candidates in metabolic diseases and endocrinology that it has licensed from Amunix. Versartis has preclinical proof-of-concept for three product candidates in its pipeline: exenatide and IL-1ra for diabetes, and hGH for growth hormone deficiency.

Further information on Versartis can be found at

SOURCE SynCo Bio Partners B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
2. SynCo Bio Partners Wins Best Contract Manufacturing Organization 2009 ViE Award
3. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
4. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
5. Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
6. AIAG and MichBio Form New Collaborative Partnership
7. ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery
8. MUSA Technology Partners Introduces Linux/Open Source Service Desk
9. Microban Partners With to Launch Yoga Mats With Zinc Antimicrobial Technology
10. Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections
11. Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... published their findings on what they believe could be a new and helpful ... the new research. Click here to read it now. , Biomarkers ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):